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Dear Sir, Polymorphic light eruption (PLE) affects 18% of people in Northern Europe (1).  It 
is characterised by a delayed-onset pruritic photo-exposed site papular eruption after sun 
exposure (2).  There is considerable heterogeneity in presentation, morphology and severity 
(3).  Iterative provocation testing with a broadband source (usually UVA) is often positive (3, 
4), whilst monochromator phototesting is normal in many patients (abnormal in 945 of 2432 
patients diagnosed with PLE who had monochromator phototesting in Dundee until 2012) 
and only rarely severely abnormal.  This contrasts with the immunological photodermatosis 
second most frequently seen in tertiary referral centres, chronic actinic dermatitis (CAD), in 
which a photo-distributed dermatitis, in association with severely abnormal broadband, often 
disproportionate ultraviolet B (UVB), photosensitivity is seen, usually also with multiple 
contact allergies.  A diagnosis of classical PLE is typically straightforward.  However, 
increasingly we have seen patients with a clinical presentation strongly suggestive of PLE, 
with markedly abnormal monochromator phototesting, raising the question as to whether this 
remains within the PLE spectrum.  We have characterised this patient group, who represent 
approximately 1% of PLE cases diagnosed in our tertiary referral photodiagnostic unit 
(Scottish Photobiology Service; SPS) over a 10-year period. 
 
We reviewed records of patients identified from the SPS database as having a clinical 
diagnosis of PLE with Severe Abnormal Phototesting Sensitivity (PLESAPS).  The criteria for 
this diagnosis were: a database diagnosis of “PLE” and a minimal erythema dose (MED) 
with at least one monochromator waveband of <50% of the lowest population normal MED.  
In practice, our database did not allow for searching based on monochromator MED values 
and patients were identified by screening records of those with a low narrowband UVB MED 
(≤ 0.05 J/cm²).  Demographic data, photosensitivity characteristics, investigation findings and 
outcomes were documented.  
 
Assessment included monochromator phototesting (5), with normal population reference 
ranges derived from healthy volunteer populations (6), narrowband UVB MED testing, 
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iterative broadband UVA (20 J/cm²; 400 W metal halide lamp; h1 filter) provocation testing 
and lupus and porphyria screening.  Diagnostic biopsy was performed where feasible and in 
all but one this was from an abnormal phototest site as patients usually did not have any 
signs of naturally provoked disease at the time of assessment due to the seasonal and 
intermittent nature of photosensitivity. 
 
Nineteen patients were studied, including three identified prospectively.  One patient had 
had a narrowband UVB MED >0.05 J/cm2 but monochromator sensitivity of <30% normal at 
335±[half-maximum bandwidth]30 nm and 365±30 nm wavebands.  Sixteen (84%) were 
female, with median age of photosensitivity onset of 29 (range 4-54) years.  Fitzpatrick skin 
types were: I (n=5), II (n=5), III (n=2), V (n=3), unspecified (n=4).  
 
The median duration of sun exposure to provoke the eruption was 30 minutes (range 
“seconds” to “hours”).  The interval between exposure to onset of rash was a median of 6 
(0.5-12) hours and rash duration was 7 (1-14) days.  Provocation through glass, clothing and 
by artificial lighting was reported by 79%, 16% and 5% respectively.  Most patients had 
involvement of arms (87%), upper chest (77%), face (69%) and back of hands (57%).   
 
Importantly, most patients presented with a seasonal, delayed onset papular/papulo-
vesicular or plaque-like clinical picture, with resolution within days and only a minority 
described swelling or perennial symptoms, thus the clinical characteristics were strongly 
suggestive of PLE (Table 1).  Most did not have any history of preceding eczema, with only 
three (16%) having a history of atopic dermatitis. 
 
Information on sunscreen use was available for 13 patients, indicating benefit in seven and 
lack of effect in six. Prescribed medication was not considered relevant in any case.  
Broadband UVA provocation testing was abnormal, with erythemal, oedematous and/or 
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papular responses in 79% of patients.  Monochromator phototesting was abnormal in all 
patients, with prominent UVAII and/or UVB sensitivity in most (Table 2). 
 
One patient had a positive ANA (1:160), but all had negative extractable nuclear antigens 
and none had features of connective tissue disease.  Plasma porphyrin analysis was 
negative in all patients.  Fourteen patients (74%) had skin biopsies taken from phototest 
sites (with the exception of one where pre-existing lesional skin was biopsied).  
Histopathology showed changes suggestive of classical PLE in 33%, eczematous features in 
39%; features supportive of phototoxicity in 11% and 17% were indeterminate.  The varying 
features, including usually mild spongiosis, were all consistent with PLE (7). 
 
Fifteen patients underwent patch testing, of which 14 (93%) had one positive reaction, with 
common allergens such as nickel and fragrance represented.  Four patients (27%) had three 
or more contact allergies.  Asteraceae allergy was seen in two subjects (13%).  Photopatch 
testing was performed in 16 patients; four had positive reactions (25%) and two of these 
patients had multiple positive photocontact reactions.  The commonest culprit was 
oxybenzone. 
 
All of the 19 patients were offered follow-up and 11 attended for repeat phototesting.  This 
was generally carried out between 6 and 12 months after initial assessment.  The diagnosis 
of only one patient subsequently changed to CAD.  This patient had a changed, worsening 
clinical picture, with development of photo-exposed site dermatitis, in combination with a 
papular response after sun exposure and worsening UVB/UVA monochromator sensitivity 
over a 5-year period.  It was felt that this patient had developed CAD on a background of 
PLE.  The clinical picture, investigation findings and diagnosis of the other 10 patients who 
had repeat phototesting remained unchanged with follow-up. 
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During follow-up, 10 patients were offered narrowband UVB phototherapy.  Of seven 
patients for whom outcome data were available, four (57%) reported benefit and three no 
improvement.  One patient was successfully treated with UVA1 phototherapy. 
 
The key characteristics of PLESAPS emerging from this patient cohort are: 
• Female preponderance (84%) 
• Age at onset <33yrs (75%) 
• Seasonal photosensitivity (79%) 
• Papular/papulovesicular rash morphology (89%) 
• Sunlight provocation through window glass (79%) 
• Severe monochromator sensitivity to UVB/ UVAII (>80%) 
• Abnormal response to UVA provocation (79%) 
• High prevalence of contact allergy (93%) 
• Potential to benefit from narrowband UVB phototherapy (57%) 
 
Whilst some of these characteristics occur in CAD, many more features are supportive of a 
diagnosis of PLE; such as predominant occurrence in young females and the clinical 
features of photosensitivity, particularly with regards to the seasonal nature, morphology and 
time-course of rash, with delayed onset and resolution over a week in most patients.  So, 
although it may be impossible to diagnose with certainty some patients in the early stages of 
CAD, we consider this group of patients to have severe PLE.   
 
Although there are shared features with classical PLE, patients with PLESAPS are more 
severely affected, with more (69%) facial involvement than expected in classical PLE.  
Furthermore, abnormal iterative UVA provocation testing showed positive responses in 79%.  
Previous studies have indicated both UVA- and UVB- wavelength dependency in PLE, with 
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disproportionate UVA dependence (3, 4).  In our patient group, 68% of patients also had 
abnormal sensitivity in the visible spectrum. 
 
The high prevalence of contact allergy in the PLESAPS group is of interest as of course 
multiple contact allergies typically occur in CAD (8).  However, there is some evidence to 
support increased contact allergy in PLE and most of our cohort had at least one positive 
patch test.  This warrants further study. 
 
The immunopathogenesis for both PLE and CAD is not yet fully understood, but both share 
features of a delayed type hypersensitivity reaction (3, 9), and CAD has been reported in 
association with PLE (9).  It is important to highlight that of those who engaged with follow-
up, the clinical picture, investigation findings and diagnosis of PLESAPS remained 
unchanged in all except one, whose clinical presentation changed and deteriorated, with 
development of photo-exposed site dermatitis and worsening of broadband abnormal 
photosensitivity over a 5-year period.  It was felt this patient had indeed developed CAD on a 
background of PLE, highlighting the need for vigilance and follow-up with repeat 
phototesting.   
 
Indeed, it is of interest to review a recent report of CAD, which included 29 patients, with 
median age at presentation of 40 years, who were of higher skin phototypes V and VI, as the 
majority had a history of atopic disease or preceding eczema of other type and photo-
exposed site dermatitis (10).  This again emphasises the clear differences from our patient 
group, with respect to demographics and clinical characteristics. 
 
Several important points can be drawn from this patient review.  There is little justification to 
split PLESAPS from the PLE spectrum.  We did initially consider that this might be a different 
diagnostic group from ‘normal’ PLE, but the findings of this review suggest that PLESAPS is 
better considered as severe PLE.  Treatment options do not significantly differ from those 
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considered for PLE in general.  The high prevalence of contact allergy supports the need for 
patch testing in this group.   
 
The identification of this group of severely affected PLE patients, with objectively severe 
abnormal monochromator phototesting, emphasises that PLE although often considered 
relatively ‘minor’ despite its important quality of life effects (11), can be a severe 
immunological photodermatosis. 
  
8 
 
Table 1: Clinical characteristics of PLESAPS in 19 patients 
Characteristics Number of Patients (%) 
Pruritus 19 (100) 
Swelling 4 (21) 
Pain 1 (5) 
Papules 17 (89) 
Vesicles 7 (37) 
Plaques 2 (11) 
Photosensitivity in UK 17 (89) 
Photosensitivity overseas 2 (11) 
Perennial symptoms  4 (21) 
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Table 2: Monochromator phototesting results in 19 patients with PLESAPS 
Waveband  ± half 
maximum bandwidth 
(nm)  
Number of patients with 
abnormal sensitivity (%) 
(n=19) 
 
Number of patients 
(%) with MED <50% 
of lowest normal dose 
(n=19) 
 
Number of patients 
(%) with MED <20% 
lowest normal dose  
(n=19) 
305±5 (UVB) 17 (89)  7 (37) 3 (16) 
335±30 (UVAII) 18 (95) 12 (63) 4 (21) 
365±30 (UVAI) 12 (63)  10 (53) 3 (16) 
400±30 (UVAI/visible) 13 (68)  10 (53) 0  
430±30 (visible) 13 (68)  2 (11) 0 
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